- 14 March
-
At the end of the last year, Novouralsk-based Medsintez Plant turned 20 years old. Alexander Petrov, Chairman of the plant's Board of Directors, told Regions of Russia about the impressive successes that the company has achieved over the years and its ambitious plans for the future.
- 22 January
-
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease. The preparations are available in the most convenient and familiar for patients dosage form – a disposable prefilled injection and have already been supplied to pharmacies.
- 13 December
-
Medsintez Plant LLC presented the latest biotechnological developments of pharmaceuticals at the largest international scientific and practical forum in the field of medicine and health care Russian Health Care Week — 2023 held from December 4 to December 8 in Moscow. The main purpose of the Forum is to facilitate the implementation of the national projects “Healthcare” and “Demography”, “Tourism and Hospitality Industry”, the federal project “Development of Medical Services Export”, as well as summarizing the results of the Year of Science and Technology in Medicine.
- 04 October
-
On September 27, as part of the business program of the GMP conference with international participation, Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, took part in a Plenary Session on the issues of regulating the circulation of medicines in Russia and the EAEU, developing import independence, and increasing export potential. The session was attended by representatives of the Ministry of Industry and Trade of the Russian Federation, the Minister of Health of the Republic of Nicaragua, the WHO Representative in Russia, a Representative of the Serbian Ministry of Health and other Russian and foreign experts. Mr. Petrov spoke about the problems that Russian pharmaceutical companies face when entering international markets and suggested possible solutions.
- Home
- Cluster members
- Ural instrument-engineering plant JSC
Ural instrument-engineering plant JSC
The main products of the Ural instrument-engineering plant are gyroscopic equipment, devices and products for integrated flight system. The development and serial production of highly demanded competitive medical equipment is an important segment in the structure of manufacture of civil products at UIMP JSC.
Contacts of the enterprise – 25 km of the Chelyabinsk Tract, Sysert District, Sverdlovsk Region, 624000
Tel./fax: — +7(343) 359-93-76, e- mail: mail@upz.ru, www.upz.ru
Brief description of medical equipment products:
Artificial lung ventilation device Aventa-U
The universal device allows artificial lung ventilation (ALV) in newborns, children and adults. The device is indispensable in maternity hospitals, perinatal centers. It allows adequate replacement of imported analogues, it is not inferior in terms of functionality, but ahead of competitors in many ways. ALV in newborns includes all modern modes for this category of patients, including HFO (oscillatory ventilation), time- cyclic ALV modes with controlled pressure, modes with the support of guaranteed tidal volume, pressure, as well as adaptive ALV modes, the operation of which based on biofeedback.
Artificial lung ventilation device Aventa-M
The ALV device is electrically driven, with advanced functions for ventilation of the lungs in adults and children aged 1 year and over. The high-end mobile device is equipped with a built-in flow generator and modern touch controls. Advanced, detailed monitoring of all key parameters, including pulse oximetry, capnography and spirometry. Possibility of remote control of ALV through a wireless Wi-Fi interface. Automatic adaptive ventilation modes have also been implemented.
Artificial lung ventilation device Potok
Designed to provide respiratory support and ALV with a mask in newborns who are in the state of apnea or severe respiratory failure in the first minutes of life after birth.
The device provides the possibility of using special breathing circuits for non-invasive ventilation of the lungs, both through a mask and through a nasal CPAP circuit. The main feature of the device and its advantage over foreign analogues is the availability of a built-in compact electric drive.
The Potok ALV device is used in maternity wards, operating rooms, ICUs of maternity hospitals and perinatal centers.
Artificial lung ventilation device Phasa-21
The Phase-21 ALV device is intended for artificial lung ventilation in hospitals, vehicles, at home. Modern, compact ventilator with microprocessor control and built- in low-pressure compressor can be used with low-pressure oxygen and 190-250 V AC, 12 and 27 V DC of on-board power supply of a motor vehicle, aircraft, helicopter. The device can be used together with the block for inhalation anesthesia. Unlike foreign analogues, the device has a built-in pulse oximetry and runs on a built-in battery for up to 10 hours.
